Jasper’s Expanding Pipeline

Jasper maintains worldwide rights to develop and commercialize JSP191 and eHSCs in all indications.

 

Product
RESEARCH
PRECLINICAL
CLINICAL
R&D PARTNER
JSP191 Conditioning
Sponsored Studies
    AML/MDS
    SCID
    Autoimmune (Lupus, Scleroderma, MS)
    Gene Therapy
    – Sickle Cell
Partner
    Gene Therapy – Fabry, Gaucher Type 1
Partner
    Gene Therapy – X-SCID
Partner
Investigator Sponsored Studies
    Fanconi’s Anemia
Partner
    Sickle Cell Disease
Partner
    Chronic Granulomatous Disease
Partner
    GATA2 MDS
Partner
Jasper eHSC Platform
    Thalassemias
    Sickle Cell Disease
    Autoimmune Diseases
Top